Zevra Therapeutics (ZVRA) Net Income towards Common Stockholders Growth (3y) (2017 - 2026)
Zevra Therapeutics (ZVRA) Net Income towards Common Stockholders Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 45.47% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 38.43% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 13.80% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -3.84% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 91.31% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Zevra Therapeutics | 570.04 Mn | 369.43 Mn | 34.32 Mn | 73.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 73.47% |
| Dec 31, 2025 | 49.61% |
| Sep 30, 2025 | 56.52% |
| Jun 30, 2025 | 72.21% |
| Mar 31, 2025 | -18.47% |
| Dec 31, 2024 | -136.46% |
| Sep 30, 2024 | -166.32% |
| Jun 30, 2024 | -23.05% |
| Mar 31, 2024 | 29.65% |
| Dec 31, 2023 | -60.00% |
| Sep 30, 2023 | -51.03% |
| Jun 30, 2023 | -70.94% |
| Mar 31, 2023 | -26.93% |
| Dec 31, 2022 | -14.33% |
| Sep 30, 2022 | -60.83% |
| Jun 30, 2022 | -37.46% |
| Mar 31, 2022 | 46.67% |
| Dec 31, 2021 | 19.51% |
| Sep 30, 2021 | 51.13% |
| Jun 30, 2021 | -2.29% |